Related Experiment Videos
Targeted retroviral infection of tumor cells by receptor cooperation
Francisco Martin1, Simon Chowdhury, Stuart J Neil
1Department of Immunology and Molecular Pathology, Windeyer Institute, 46 Cleveland Street, London W1T 2AH, United Kingdom.
Abstract:
Retroviruses expressing two different receptor-binding domains linked by proline-rich spacers infect only cells expressing both retroviral receptors (Valsesia-Wittman et al., EMBO J. 6:1214-1223, 1997). Here we apply this receptor cooperation strategy to target human tumor cells by linking single-chain antibodies recognizing tumor antigens via proline-rich spacers to the 4070A murine leukemia virus surface protein.
Insights
This study engineered retroviruses to target human tumor cells. By linking tumor-targeting antibodies to viral proteins, researchers enabled virus entry only into cells expressing specific tumor antigens.
Area of Science:
- Oncology
- Virology
- Molecular Biology
Background:
- Retroviruses can be engineered to target specific cells.
- Previous work demonstrated that retroviruses with dual receptor-binding domains require cells to express both receptors for infection.
- This receptor cooperation strategy offers a method for targeted viral delivery.
Purpose of the Study:
- To adapt the receptor cooperation strategy for targeting human tumor cells.
- To engineer retroviruses that specifically infect cells expressing tumor antigens.
Main Methods:
- Linking single-chain antibodies recognizing tumor antigens to the 4070A murine leukemia virus surface protein.
- Utilizing proline-rich spacers to connect antibody domains and viral proteins.
- Applying the receptor cooperation principle to achieve targeted viral entry.
Main Results:
- Successfully engineered retroviruses capable of targeting tumor cells.
- Demonstrated the potential for receptor cooperation in directing viral entry to specific cell types.
- Established a novel method for targeted retroviral delivery to human tumors.
Conclusions:
- The receptor cooperation strategy can be effectively applied to target human tumor cells.
- Engineered retroviruses show promise for targeted cancer therapy.
- This approach enhances the specificity of viral targeting in oncological applications.